New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 7, 2014
13:55 EDTRDY, TEVATeva won't be meaningfully hurt soon by new Copaxone filing, says BMO Capital
After Teva (TEVA) confirmed that it received the first paragraph IV notice for the 3x per week version of its Copaxone drug from Dr. Reddy's (RDY), BMO Capital said it had expected companies to seek to market a generic version of the latest Copaxone formulation, but was surprised that Dr. Reddy's took this action. The firm notes that Teva's decision to file a lawsuit against Dr. Reddy over the application will trigger a 30 month stay of approval of the generic version,. BMIO Capital says that investors should keep this issue on their radar, but the firm does not expect Teva to be meaningfully hurt in the near-term by this development. It keeps an Outperform rating on Teva.
News For TEVA;RDY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 16, 2015
12:35 EDTTEVAFDA denies Teva attempt to block generic Copaxone
Subscribe for More Information
06:16 EDTTEVAFormer Teva CEO appointed to position of CEO at Ovid Therapeutics
Ovid Therapeutics, a privately held biopharmaceutical company focused on developing therapies for rare and orphan diseases of the brain, appointed Dr. Jeremy Levin as CEO. Levin has served as Chairman of Ovid since 2014 and will continue to serve in this role. Most recently, Levin served as CEO of Teva.
April 15, 2015
19:34 EDTTEVAVIVUS files patent infringement lawsuit against Teva
Subscribe for More Information
April 14, 2015
08:03 EDTTEVATeva, Eagle announce NDA for bendamustine HCI accepted for filing
Subscribe for More Information
April 13, 2015
07:56 EDTTEVAMylan, Teva, Perrigo price targets raised at JPMorgan
Subscribe for More Information
April 9, 2015
09:51 EDTTEVAPerrigo did not expect Mylan takeover letter, CNBC's Faber reports
Perrigo (PRGO) did not expect the takeover letter it received from Mylan (MYL), CNBC's David Faber reports, citing sources. Perrigo will take its time in deciding what its next steps are, Faber added. Shares of Mylan are up 3% in early trading, which is being attributed, at least in part, to speculation the company could be a takeover target itself. Analysts this morning mentioned Teva (TEVA) as a potential acquirer of Mylan. Chatter this morning has Pfizer (PFE) also potentially interested in the EpiPen maker
08:30 EDTTEVAPotential bid for Mylan by Teva could provide profound synergies, says Cowen
Subscribe for More Information
08:10 EDTTEVALeerink sees 70% chance of Mylan buying Perrigo with raised bid
Subscribe for More Information
06:20 EDTTEVATeva bid for Mylan possible, but challenging, says Citigroup
Subscribe for More Information
06:15 EDTTEVACiti does not see much strategic sense in Mylan, Perrigo deal
Subscribe for More Information
05:49 EDTTEVAStocks with implied volatility movement; MYL TEVA
Subscribe for More Information
April 8, 2015
16:22 EDTTEVAOn The Fly: Closing Wrap
Subscribe for More Information
14:23 EDTTEVAAdditional bidders for Perrigo could emerge after Mylan offer, says Stifel
Subscribe for More Information
13:07 EDTTEVAMylan bid for Perrigo makes strategic sense, says JPMorgan
Subscribe for More Information
12:37 EDTTEVATeva downgraded to Hold from Buy at Standpoint Research
Subscribe for More Information
12:17 EDTRDYOn The Fly: Midday Wrap
Subscribe for More Information
07:16 EDTTEVAMylan one of the cheapest names in Specialty Pharma, says JPMorgan
Subscribe for More Information
05:10 EDTRDYDr. Reddy's Labs files three NDAs with FDA
Dr. Reddy's Laboratories and its subsidiary, Promius Pharma, announced the filing of three 505(b)(2) New Drug Applications, or NDAs, with the FDA. The three NDAs - DFD-01, DFD-09, and DFN-11, are in support of Dr. Reddy’s Proprietary Products group, focused on developing and commercializing therapies in dermatology and neurology. DFD-01 and DFD-09 are the first dermatology applications submitted to the NDA that have been fully developed leveraging in-house capabilities. DFD-01 is a corticosteroid delivered in a novel non-irritating spray platform, intended for the treatment of patients suffering from psoriasis. DFD-09 is a modified release oral tetracycline intended for the treatment of rosacea. DFN-11 is the first development program filed in support of a newly created vertical, focused on the U.S. neurology market. DFN-11 is a drug-device combination product intended to treat acute migraine episodes in certain patient populations who are inadequately managed with existing treatment regimens.
April 7, 2015
15:24 EDTTEVATeva price target raised to $75 from $64 at BMO Capital
BMO Capital raised its EPS estimates for Teva (TEVA) and increased its price target on the stock to $75 from $64 on account of the expected launch of a treatment for chorea associated with Huntington’s disease in 3Q16 and a launch of a tardive dyskinesia drug in 3Q17 following the company's deal to buy Auspex (ASPX). The firm maintains its Outperform rating on Teva shares.
April 6, 2015
05:56 EDTTEVATeva battles possible generic Copaxone competitors, Globes reports
A citizen's petition has been filed by Teva with the FDA against possible generic competition to its MS treatment Copaxone beginning in September, Globes reports. The FDA has previously ruled that it was "too early" to discuss the matter. Reference Link
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use